Skip to main navigation Skip to search Skip to main content

Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study

  • Y. Benavente
  • , G. Mbisa
  • , N. Labo
  • , D. Casabonne
  • , N. Becker
  • , M. Maynadie
  • , L. Foretova
  • , P. L. Cocco
  • , A. Nieters
  • , A. Staines
  • , P. Bofetta
  • , P. Brennan
  • , D. Whitby
  • , S. De Sanjosé
  • Institute Catala Oncologia
  • CIBER Epidemiología y Salud Pública (CIBERESP)
  • SAIC
  • German Cancer Research Center
  • Université de Bourgogne
  • Masaryk Memorial Cancer Institute
  • University of Cagliari
  • University of Freiburg
  • University College Dublin
  • International Agency for Research on Cancer

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background: Kaposi's sarcoma-associated herpes virus is associated with primary effusion lymphoma and multicentric Castleman's disease.Methods: Seropositivity to lytic and latent Kaposi's sarcoma herpes virus (KSHV) antigens were examined in 2083 lymphomas and 2013 controls from six European countries. Results: Antibodies against KSHV latent and lytic antigens were detectable in 4.5% and 3.4% of controls, respectively, and 3.6% of cases (P0.05). The KSHV seropositivity was associated with splenic marginal zone lymphoma (SMZL) (odds ratio (OR)4.11, 95% confidence interval (CI)1.57-10.83) and multiple myeloma (OR0.31, 95% CI0.11-0.85).Conclusion:The KSHV is unlikely to contribute importantly to lymphomagenesis among immunocompetent subjects. However, the observed association with SMZL may underline a chronic antigen mechanism in its aetiology.

Original languageEnglish
Pages (from-to)1768-1771
Number of pages4
JournalBritish Journal of Cancer
Volume105
Issue number11
DOIs
StatePublished - Nov 22 2011

Keywords

  • epidemiology
  • human herpes virus 8
  • Kaposi's sarcoma-associated herpes virus
  • lymphoma
  • serology

Fingerprint

Dive into the research topics of 'Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study'. Together they form a unique fingerprint.

Cite this